Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?
复制标题
DOI:
10.1186/s13023-021-01758-9
复制
发表时间:
2021-03-04
影响因子:
3.7
通讯作者:
Rybalka E
中科院分区:
文献类型:
--
作者:
Kourakis S;Timpani CA;Campelj DG;Hafner P;Gueven N;Fischer D;Rybalka E
Pharmacological corticosteroid therapy is the standard of care in Duchenne Muscular Dystrophy (DMD) that aims to control symptoms and slow disease progression through potent anti-inflammatory action. However, a major concern is the significant adverse effects associated with long term-use. This review discusses the pros and cons of standard of care treatment for DMD and compares it to novel data generated with the new-wave dissociative corticosteroid, vamorolone. The current status of experimental anti-inflammatory pharmaceuticals is also reviewed, with insights regarding alternative drugs that could provide therapeutic advantage. Although novel dissociative steroids may be superior substitutes to corticosteroids, other potential therapeutics should be explored. Repurposing or developing novel pharmacological therapies capable of addressing the many pathogenic features of DMD in addition to anti-inflammation could elicit greater therapeutic advantages.
登录
查看更多内容
影响因子:
4
作者:
Creelan BC;Gabrilovich DI;Gray JE;Williams CC;Tanvetyanon T;Haura EB;Weber JS;Gibney GT;Markowitz J;Proksch JW;Reisman SA;McKee MD;Chin MP;Meyer CJ;Antonia SJ
通讯作者:
Antonia SJ
影响因子:
4.1
作者:
Coutinho, Agnes E.;Chapman, Karen E.
通讯作者:
Chapman, Karen E.
影响因子:
3.4
作者:
ANGELINI, C;PEGORARO, E;COSTA, C
通讯作者:
COSTA, C
影响因子:
5.1
作者:
Barber, Brent J.;Andrews, Jennifer G.;Cunniff, Christopher
通讯作者:
Cunniff, Christopher
影响因子:
5.8
作者:
Breuer, Johanna;Herich, Sebastian;Schwab, Nicholas
通讯作者:
Schwab, Nicholas